20n Bio is a VC-backed start-up dedicated to the computational design of novel protein therapeutics. Launched in 2021 and located in Malvern PA, its mission is addressing unmet medical needs by leveraging artificial intelligence to generate protein drugs in silico with desired biophysical, functional, and pharmacological properties.
The company uses advanced computational methods and high-throughput screening technologies to design new protein drugs, which target traditionally small molecules that cannot be drugged, thereby greatly broadening the boundaries of drugs.
Total Funding: $3.3 M
Funding Stage: Seed
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2021
